Clinical trials: Opioid-Induced Disorders
Opioid-use Disorder
Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)
This study seeks to test a new model of care (ID/LAB) in which opioid use disorder (OUD) is managed by infectious disease (ID) specialists and hospitalists concurrent with management of the OUD-related infections, using…
- Trial name
- COMMIT (NCT04180020)
- Testing
- ID/LAB, TAU
- Where
- 3 sites in United States
- Volunteers
- 171 people
- Sponsor
- Yale University
Opioid Use
Life Care Specialists (LCS) With a Focus on Patient Pain Management and Prevention of Substance Misuse
The overall hypothesis of this randomized-controlled trial is that the introduction of a Life Care Specialist (LCS) as a novel member of the clinical care team will help reduce opioid utilization, decrease pain scores, and…
- Trial name
- NCT04154384
- Testing
- Life Care Specialist (LCS) Intervention, Clinical Coordination with Referrals, Pilot Study of Pain Management Strategies
- Where
- United States
- Volunteers
- 333 people
- Sponsor
- Emory University
Opiate Dependence
Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone
This study is a collaboration between the University of Pennsylvania, the Philadelphia Prison System, and the North East Treatment Center (NETSteps).
- Trial name
- OAPXRNTX (NCT02617628)
- Testing
- extended release naltrexone
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Opioid-use Disorder
A Pilot Feasibility Study of Mindfulness-Oriented Recovery Enhancement With Pregnant Women With Opioid Use Disorder
Thirty pregnant women with substance use disorder will be recruited to participate in eight sessions of MORE.
- Trial name
- NCT04824521
- Testing
- Mindfulness-Oriented Recovery Enhancement
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Montana
Opioid Use Disorder
TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051
This is an observational, "ancillary study" intended to describe opioid use among opioid use disorder patients following their discharge into the community from inpatient detoxification and/or short-term residential treatment…
- Trial name
- NCT02730403
- Testing
- Treatment As Usual
- Where
- 5 sites in United States
- Volunteers
- 211 people
- Sponsor
- NYU Langone Health
Opiate Dependence
Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail
This pilot study's primary aim is to compare rates of sustained opioid relapse, defined as self-reported opioid use >50% (>15 of 30) of days during the first 30 days following release from jail, among persons treated with XR-NTX…
- Trial name
- NCT01180647
- Testing
- Extended-Release Naltrexone, Motivational Enhancement Counseling
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- NYU Langone Health
Constipation
Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with chronic non-malignant pain who have Opioid-Induced Constipation (OIC).
- Trial name
- NCT00529087
- Testing
- N-methylnaltrexone bromide (MOA-728)
- Where
- 78 sites in United States
- Volunteers
- 460 people
- Sponsor
- Bausch Health Americas, Inc.
Opioid-Induced Constipation
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC) in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901341
- Testing
- CB-5945
- Volunteers
- 44 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Opioid-use Disorder, Opioid Use
PRescribing INterventions for Chronic Pain Via the Electronic Health Record Study - Current Opioid-User Population
The objective of this research is to assess the effects of electronic health record (EHR)-based decision support tools on primary care provider (PCP) decision-making around pain treatment and opioid prescribing.
- Conditions
- Opioid-use Disorder, Opioid Use, Opioid Abuse
- Trial name
- PRINCE (NCT04601480)
- Testing
- Choice Architecture Nudge, PMP Integration & Nudge
- Where
- United States
- Volunteers
- 309 people
- Sponsor
- University of Minnesota
Opioid-Related Disorders
Trial of Adherence App for Buprenorphine Treatment (TAAB) Study
The purpose of this study is to pilot test a smartphone application that allows video-based directly observed therapy for participants receiving buprenorphine treatment for opioid use disorder in office-based settings.
- Trial name
- NCT03779997
- Testing
- Video-based DOT Application
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of Washington
Pain, Osteoarthritis, Hip
Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee
This clinical trial tests the pain relieving effectiveness of OROS hydromorphone, a once-daily formulation of a strong opioid against placebo in patients, who are suffering from pain due to osteoarthritis of the hip or the knee…
- Conditions
- Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
- Trial name
- NCT00980798
- Testing
- OROS hydromorphone HCl
- Where
- 12 sites in Czechia, Romania and 2 more
- Volunteers
- 288 people
- Sponsor
- Janssen-Cilag International NV
Opioid Induced Constipation (OIC)
A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)
Study (07-IN-NX003) is a Phase 2, multi-center, placebo-controlled, double-blind, randomized, dose-escalation trial. It is designed to investigate the safety, efficacy and tolerability of NKTR-118 (PEG-naloxol) in patients with…
- Trial name
- NCT00600119
- Testing
- NKTR-118
- Where
- 33 sites in United States
- Volunteers
- 207 people
- Sponsor
- AstraZeneca
Opioid Use Disorder
Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants
The purpose of this open label study is to characterise the absorption, metabolism, excretion, and mass balance of [14C]-IDV184001AN ([14C]-IDV184001) in healthy adult male participants.
- Trial name
- NCT05974046
- Testing
- [14C]IDV184001AN
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Opioid Abuse, Opioid Dependence
A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
Buprenorphine is an approved medication for the treatment of opioid dependence. It is typically administered once daily as a sublingual tablet combined with naloxone (i.e., Suboxone).
- Trial name
- NCT01136356
- Testing
- buprenorphine, morphine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Johns Hopkins University
Opioid Dependency
Transdermal Electroacupuncture for Opioid Detoxification
This single-blind, randomized clinical trial tests whether electroacupuncture, provided as an adjunctive treatment, improves outcomes among patients receiving inpatient opioid detoxification from opioids.
- Trial name
- NCT00742170
- Testing
- Electroacupuncture
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Mclean Hospital
Opioid-Related Disorders
Improving Health and Employment Outcomes Through Workplace Opioid Policies
Evaluate the feasibility of implementing workplace opioid guidelines in the construction trades; define and collect measures of implementation and efficacy.
- Trial name
- NCT05387408
- Testing
- Best Practice Health and Employment Opioid-related Policies
- Where
- United States
- Volunteers
- 4,939 people
- Sponsor
- Washington University School of Medicine
Opioid Overdose
Project OOPEN: Opioid Overdose Prevention, Education and Intervention
This prospective, randomized emergency department trial will study the effectiveness of an intervention that combines opioid overdose prevention, education and intervention that includes take home naloxone with brief behavioral…
- Trial name
- OOPEN (NCT01788306)
- Testing
- OOPEN+BBCC
- Where
- 3 sites in United States
- Volunteers
- 256 people
- Sponsor
- University of Washington
Opioid Dependence
Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence
Opioid dependence is a substantial problem associated with significant morbidity and mortality. Extended-release naltrexone has been found effective at reducing opioid use and maintaining abstinence, but its use has been limited…
- Trial name
- NCT02437344
- Testing
- CI-581aa, Naltrexone titration and XR-NTX initiation
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- New York State Psychiatric Institute
Substance-Related Disorders
Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use
This study examines whether isolated doses of d-cycloserine enhance the efficacy of an exposure-based cognitive-behavioral treatment for chronic and treatment refractory substance dependence.
- Trial name
- NCT00430573
- Testing
- D-cycloserine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Boston University Charles River Campus
Opioid Use Disorders
Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
The aim of this trial is to assess the clinical utility, effectiveness, and cost implications of treatment for incarcerated offenders with opioid use disorders who are randomly assigned to one of three treatment conditions to…
- Trial name
- IPOD (NCT02110264)
- Testing
- XR-NTX, XR-NTX+PN, ETAU
- Where
- United States
- Volunteers
- 151 people
- Sponsor
- University of California, Los Angeles